[CAS NO. 1929519-13-0] Zelatriazin

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1929519-13-0]

Catalog

HY-132228

Brand

MCE

CAS

1929519-13-0

DESCRIPTION [1929519-13-0]

Overview

MDL	MFCD32858822
Molecular Weight	392.33
Molecular Formula	C18H15F3N4O3
SMILES	O=C(N[C@H](C1=CC=C(OC(F)(F)F)C=C1)C)CN2N=NC3=CC=CC=C3C2=O

For research use only. We do not sell to patients.

Summary

TAK-041 is a potent and selective GPR139 agonist with an EC ₅₀ of 22 nM. TAK-041 has the potential for the research of negative symptoms associated with schizophrenia ^[1] .

In Vivo

TAK-041 (0.03-3 mg/kg; P.o.) improves social behavior in BALB/c mice ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice ^[1]
Dosage:	0.03, 0.3, and 3 mg/kg
Administration:	P.o.
Result:	Dose-dependently improved the social behavior of BALB/c mice.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02748694	Neurocrine Biosciences\|Takeda	Healthy Volunteers\|Schizophrenia	May 9, 2016	Phase 1
NCT05165394	Neurocrine Biosciences	Anhedonia\|Major Depressive Disorder	November 30, 2021	Phase 2
NCT03319953	Neurocrine Biosciences\|Takeda	Stable Schizophrenia	December 21, 2017	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 254.89 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5489 mL	12.7444 mL	25.4887 mL
5 mM	0.5098 mL	2.5489 mL	5.0977 mL
10 mM	0.2549 mL	1.2744 mL	2.5489 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Reichard HA, et al. Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia [published online ahead of print, 2021 Jul 14]. J Med Chem. 2021;10.1021/acs.jmedchem.1c00820.